Bbva Compass Bancshares Inc. boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 7.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,925 shares of the medical research company’s stock after purchasing an additional 1,796 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Thermo Fisher Scientific were worth $5,094,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC increased its position in Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after buying an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Thermo Fisher Scientific during the second quarter worth $108,000. Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the second quarter worth $113,000. Ropes Wealth Advisors LLC increased its position in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC purchased a new position in Thermo Fisher Scientific during the second quarter worth $138,000. 85.32% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at $192.75 on Thursday. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20. The firm has a market capitalization of $77,364.04, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter last year, the firm earned $2.03 earnings per share. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. equities analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 10.19%.

ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/23/thermo-fisher-scientific-inc-tmo-shares-bought-by-bbva-compass-bancshares-inc.html.

TMO has been the subject of several recent research reports. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen and Company reissued a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $205.71.

In related news, VP Peter E. Hornstra sold 3,894 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. Insiders sold 60,420 shares of company stock worth $11,308,477 in the last quarter. 0.49% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.